Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2292767 in Healthy Participants Who Smoke Cigarettes

NCT03045887 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: GSK2292767 50 μg
DRUG: GSK2292767 500 μg
DRUG: Placebo

Sponsor

GlaxoSmithKline